CombiGene’s former Director Preclinical Development Annika Ericsson has taken over the role of the company’s Chief Scientific Officer. BioStock contacted Ericsson to learn more about her near-term priorities and long-term goals.
– We know that CG01 has great potential thanks to the out-licensing to Spark. I also see enormous potential in our pain project, which shows impressive preclinical data, says Annika Ericsson.
Read the article from BioStock here: She is CombiGene’s new CSO – BioStock